Tech Frontiers

This coming January will mark two years since we launched Tech Frontiers and its predecessor, Biotech Frontiers. During that time, we’ve compiled an extraordinary track record: Eight of our recommendations have appreciated over 100% and many others have appreciated at least 50%. In the meantime, in our biotech portfolio, we encountered only two meaningful losers

In today’s Daily Journal, Porter tells readers everything they need to know about the latest medical breakthrough and how to make millions of dollars investing in it over the next decade.

Despite the rally in biotech we’ve seen this year, the opportunity today is now even better than it was when Erez Kalir launched his biotech newsletter in January of 2024. Remember, Porter writes today, It only takes one biotech bull market to make you rich.

If you want to succeed in investing – or in any field where competition is fierce – take a page from this investor’s book… and play the game differently than everyone else. Erez Kalir explains how.

Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for